Medical treatment
    2.
    发明授权
    Medical treatment 失效
    药物治疗

    公开(公告)号:US06617360B1

    公开(公告)日:2003-09-09

    申请号:US09702125

    申请日:2000-10-30

    IPC分类号: A61K31135

    CPC分类号: A61K31/135 Y10S514/866

    摘要: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.

    摘要翻译: 式I的化合物或其药学上可接受的盐,其中R 1和R 2独立地为H或甲基(例如N,N-二甲基-1- [1-(4-氯苯基)环丁基] -3-甲基丁基胺盐酸盐, 其一水合物的形式)用于降低葡萄糖耐受性和非胰岛素依赖性糖尿病受损患者的胰岛素抵抗。

    Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of
diabetes complications
    3.
    发明授权
    Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications 有权
    使用2-(2-吗啉代苯基)胍衍生物治疗糖尿病并发症

    公开(公告)号:US6133267A

    公开(公告)日:2000-10-17

    申请号:US319881

    申请日:1999-06-14

    CPC分类号: A61K31/5375

    摘要: A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate) is used for inhibiting the formation of advanced glycosylation end-products, and for the treatment and/or prophylaxis of long-term complications associated with diabetes, such as atherosclerosis, nephropathy, neuropathy and retinopathy.

    摘要翻译: PCT No.PCT / EP97 / 06831 Sec。 371日期1999年6月14日第 102(e)1999年6月14日PCT 1997年12月8日PCT PCT。 第WO98 / 26782号公报 日期:1998年6月25日一种式I化合物或其药学上可接受的盐,其中R 1和R 2独立地为H或甲基(例如1,1-二甲基-2-(2-吗啉代苯基)胍延胡索酸酯)用于抑制 形成先进的糖基化终产物,以及用于治疗和/或预防与糖尿病相关的长期并发症,例如动脉粥样硬化,肾病,神经病变和视网膜病变。

    Use of sibutramine analogues to prevent the development of diabetes
    4.
    发明授权
    Use of sibutramine analogues to prevent the development of diabetes 有权
    使用西布曲明类似物来预防糖尿病的发展

    公开(公告)号:US06174925B1

    公开(公告)日:2001-01-16

    申请号:US09254924

    申请日:1999-03-17

    IPC分类号: A61K31135

    CPC分类号: A61K31/135 Y10S514/866

    摘要: A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.

    摘要翻译: 式(I)化合物或其药学上可接受的盐,其中R 1和R 2独立地为H或甲基(例如N,N-二甲基-1- [1-(4-氯苯基)环丁基] -3-甲基丁基胺盐酸盐 任选地以其一水合物的形式)用于降低葡萄糖耐受性和非胰岛素依赖性糖尿病受损患者的胰岛素抵抗。